GNH USA

Europe — EMA

Ornique (Ethinylestradiol, Etonogestrel)

GNH USA supplies Ornique (Ethinylestradiol/Etonogestrel), a combined estrogen‑progestogen contraceptive for prevention of pregnancy.

Ethinylestradiol, Etonogestrel

Request sourcing

1
Pack/s

What is Ethinylestradiol, Etonogestrel?

Ethinylestradiol and Etonogestrel, the active ingredients in Ornique, are a combined estrogen‑progestogen contraceptive presented as a vaginal ring for vaginal use. The ring releases hormones steadily to inhibit ovulation and provide reliable contraception for women of reproductive age.

GNH USA supplies Ornique as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets. The company adheres to stringent quality standards and provides reliable logistics for timely delivery to healthcare providers.

What is Ethinylestradiol, Etonogestrel used for?

Ornique, a combined estrogen‑progestogen contraceptive, is indicated for preventing pregnancy.

- Prevention of pregnancy: provides reliable contraceptive effect for women of reproductive age. - Family planning: enables controlled spacing of pregnancies. - Menstrual cycle regulation: may reduce menstrual bleeding and dysmenorrhea.

What are the side effects of Ethinylestradiol, Etonogestrel?

Ornique may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects: - Nausea or mild gastrointestinal upset. - Breast tenderness or enlargement. - Headache or migraine. - Mood swings or emotional changes. - Spotting or breakthrough bleeding. - Vaginal discharge or irritation.

Serious or Rare Side Effects: - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. - Hypertension or significant blood‑pressure elevation. - Hepatic adenoma or other liver abnormalities. - Severe allergic reaction (anaphylaxis, angioedema). - Depression or worsening of mood disorders. - Visual disturbances or ocular complications.

What precautions apply to Ethinylestradiol, Etonogestrel?

Before prescribing Ornique, clinicians should evaluate individual risk factors and contraindications.

- Contraindicated in pregnancy: product is classified Category X and must not be used. - Avoid in smokers over 35 years: increased risk of cardiovascular events. - Assess history of thromboembolic disorders: hormonal contraception may elevate clot risk. - Monitor blood pressure regularly: estrogen‑progestogen combinations can raise systolic pressure. - Consider liver disease: impaired metabolism may alter hormone levels. - Store at below 25°C: keep in the original packaging, protect from moisture and heat.

What does Ethinylestradiol, Etonogestrel interact with?

Ornique can interact with several drug classes, affecting efficacy or safety.

Major Interactions (Avoid): - CYP3A4 enzyme inducers (e.g., rifampin, phenytoin, St. John’s wort): may lower hormone levels and reduce contraceptive effectiveness. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase hormone exposure and heighten side‑effect risk. - Hormonal therapy for estrogen‑dependent cancers: contraindicated due to opposing mechanisms.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may increase bleeding tendency. - Antidepressants (e.g., SSRIs): may exacerbate mood changes. - Antihypertensives: hormonal contraceptives can affect blood‑pressure control.

Frequently asked questions

What is Ornique used for?+
Ornique is a combined estrogen‑progestogen vaginal ring indicated for the prevention of pregnancy. It provides a steady release of hormones that suppress ovulation, thicken cervical mucus, and alter the endometrium, offering a reliable, reversible contraceptive option for women of reproductive age.
How does Ethinylestradiol/Etonogestrel work in Ornique?+
The ethinylestradiol component mimics natural estrogen, while etonogestrel acts as a progestogen. Together they inhibit the hypothalamic‑pituitary‑gonadal axis, reducing luteinizing hormone and follicle‑stimulating hormone release, which prevents ovulation. The progestogen also thickens cervical mucus and modifies the uterine lining to impede fertilisation and implantation.
What is the usual dose of Ornique?+
The dosing regimen for Ornique is determined by the prescribing healthcare professional. Typically, a vaginal ring is inserted and left in place for a specified period (often three weeks) followed by a ring‑free interval, but the exact schedule must be individualized and confirmed by the prescriber.
Is Ornique safe to use during pregnancy or while breastfeeding?+
Ornique is classified as Pregnancy Category X, meaning it must not be used during pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as hormonal exposure may affect milk production and infant development. Women should discontinue use if they become pregnant.
How do I order Ornique from GNH USA?+
To order Ornique, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control), and import documentation.
How does Ornique compare with other combined hormonal contraceptives?+
Ornique delivers hormones via a vaginal ring, offering continuous low‑dose exposure and eliminating daily oral dosing. Compared with combined oral contraceptives, the ring may provide more stable hormone levels, reduced gastrointestinal side effects, and improved adherence, though both share similar efficacy and safety profiles when used correctly.
What are the storage requirements for Ornique?+
Ornique should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture, direct sunlight, and excessive heat. Maintaining these conditions helps preserve the integrity of the hormone‑release system throughout its shelf life.
How is Ornique administered?+
Ornique is a flexible vaginal ring that is inserted into the vagina by the user or a healthcare professional. The ring remains in place for the prescribed duration (commonly three weeks) and is then removed for a ring‑free interval, after which a new ring is inserted to continue contraception.
What are the most serious risks associated with Ornique?+
Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, hypertension, severe allergic reactions, and rare hepatic tumors. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should avoid using Ornique.
Who should not use Ornique?+
Ornique is contraindicated in women who are pregnant, have known or suspected estrogen‑dependent tumors, have active or past thromboembolic disease, have uncontrolled hypertension, have severe liver disease, or are smokers aged 35 years or older. It should also be avoided in individuals with known hypersensitivity to any component of the ring.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Ethinylestradiol, Etonogestrel
Route
Vaginal Use
Manufacturer
Uab Exeltis Baltics
Origin
EU

Related products

Adalina

Adalina

Ethinylestradiol, Etonogestrel

Biomo Pharma Gmbh
EU
Adaring

Adaring

Ethinylestradiol, Etonogestrel

Adamed Pharma S.A.
EU
Anette

Anette

Ethinylestradiol, Etonogestrel

Lifewell - Pharmaceutical & Healthcare, Lda.
EU
Circlet

Circlet

Ethinylestradiol, Etonogestrel

Organon Belgium B.V.
EU